Alakananda Basu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3188170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701

 $_{2}$ Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 702 Td (edition 1,430)

3	Cellular Responses to Cisplatin-Induced DNA Damage. Journal of Nucleic Acids, 2010, 2010, 1-16.	1.2	361
4	The potential of protein kinase C as A target for anticancer treatment. , 1993, 59, 257-280.		193
5	The Emerging Roles of mTORC1 in Macromanaging Autophagy. Cancers, 2019, 11, 1422.	3.7	180
6	Regulation of Autophagy by Kinases. Cancers, 2011, 3, 2630-2654.	3.7	158
7	Protein kinase Cε makes the life and death decision. Cellular Signalling, 2007, 19, 1633-1642	3.6	146
8	Two Faces of Protein Kinase CÎ [°] : The Contrasting Roles of PKCÎ [°] in Cell Survival and Cell Death. Scientific World Journal, The, 2010, 10, 2272-2284.	2.1	116
9	Involvement of protein kinase C-? in DNA damage-induced apoptosis. Journal of Cellular and Molecular Medicine, 2003, 7, 341-350.	3.6	103
10	Regulation of Caspase Activation and <i>cis</i> -Diamminedichloroplatinum(II)-Induced Cell Death by Protein Kinase C. Biochemistry, 1999, 38, 4245-4251.	2.5	85
11	Protein Kinase Cl̈µ Activates Protein Kinase B/Akt via DNA-PK to Protect against Tumor Necrosis Factor-α-induced Cell Death. Journal of Biological Chemistry, 2006, 281, 22799-22807.	3.4	83
12	The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy. , 2022, 230, 107943.		79
13	Proteolytic Activation of Protein Kinase C-ε by Caspase-mediated Processing and Transduction of Antiapoptotic Signals. Journal of Biological Chemistry, 2002, 277, 41850-41856.	3.4	75
14	Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cl´. Biochemical and Biophysical Research Communications, 2005, 334, 1068-1073.	2.1	75
15	A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. Toxicology Letters, 1990, 50, 123-135.	0.8	71
16	Synthesis and biological studies of simplified analogs of lyngbyatoxin A; use of an isoxazoline-based indole synthesis. Quest for protein kinase C modulators. Journal of the American Chemical Society, 1989, 111, 6228-6234.	13.7	64
17	Synthesis of structural analogs of lyngbyatoxin A and their evaluation as activators of protein kinase C. Journal of Medicinal Chemistry, 1991, 34, 2420-2430.	6.4	53
18	The Multifunctional Protein Kinase C-ε in Cancer Development and Progression. Cancers, 2014, 6, 860-878.	3.7	53

#	Article	IF	CITATIONS
19	Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1199.	4.1	52
20	Differential Sensitivity of Breast Cancer Cells to Tumor Necrosis Factor-α: Involvement of Protein Kinase C. Biochemical and Biophysical Research Communications, 2001, 280, 883-891.	2.1	44
21	S6 Kinase 2 Promotes Breast Cancer Cell Survival via Akt. Cancer Research, 2011, 71, 2590-2599.	0.9	44
22	Autophagy in breast cancer and its implications for therapy. American Journal of Cancer Research, 2013, 3, 251-65.	1.4	42
23	Synthesis, molecular modeling, 2-D NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C. Journal of the American Chemical Society, 1993, 115, 3957-3965.	13.7	38
24	Overexpression of Protein Kinase C-ĥ Attenuates Caspase Activation and Tumor Necrosis Factor-α-Induced Cell Death. Biochemical and Biophysical Research Communications, 2000, 279, 103-107.	2.1	36
25	Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1. Clinical Cancer Research, 2005, 11, 6730-6737.	7.0	36
26	The Involvement of Novel Protein Kinase C Isozymes in Influencing Sensitivity of Breast Cancer MCF-7 Cells to Tumor Necrosis Factor-α. Molecular Pharmacology, 1998, 53, 105-111.	2.3	35
27	Protein kinase C-ε protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1893-1900.	4.9	35
28	Further studies on the activation of glucocerebrosidase by a heat-stable factor from Gaucher spleen. Archives of Biochemistry and Biophysics, 1985, 236, 98-109.	3.0	34
29	Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. International Journal of Cancer, 1995, 63, 597-603.	5.1	34
30	Down-regulation of Caspase-2 by Rottlerin via Protein Kinase C-Â-Independent Pathway. Cancer Research, 2008, 68, 2795-2802.	0.9	34
31	Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. International Journal of Cancer, 1995, 62, 457-460.	5.1	31
32	Akt Isoforms: A Family Affair in Breast Cancer. Cancers, 2021, 13, 3445.	3.7	31
33	Protein Kinase C-Îμ Promotes EMT in Breast Cancer. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S13640.	1.1	27
34	Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease. Archives of Biochemistry and Biophysics, 1985, 243, 28-34.	3.0	26
35	Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C. Biochemistry, 1992, 31, 3824-3830.	2.5	24
36	Proteolytic Cleavage of p70 Ribosomal S6 Kinase by Caspase-3 during DNA Damage-Induced Apoptosis. Biochemistry, 2009, 48, 1474-1480.	2.5	24

Alakananda Basu

#	Article	IF	CITATIONS
37	Regulation of p53 stabilization by DNA damage and protein kinase C. Molecular Cancer Therapeutics, 2002, 1, 861-7.	4.1	24
38	Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity tocis-diamminedichloroplatinum(II). International Journal of Cancer, 1994, 58, 587-591.	5.1	18
39	Cisplatin resistance is associated with deregulation in protein kinase C-Î′. Biochemical and Biophysical Research Communications, 2004, 316, 1002-1008.	2.1	17
40	Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression. Cancer Chemotherapy and Pharmacology, 2010, 66, 945-952.	2.3	16
41	Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4040-4045.	2.4	16
42	Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2. PLoS ONE, 2017, 12, e0173854.	2.5	16
43	Novel regulation of protein kinase C-η. Biochemical and Biophysical Research Communications, 2012, 425, 836-841.	2.1	14
44	Regulation of Autophagy by Protein Kinase C-ε in Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4247.	4.1	14
45	Potentiation of Tumor Necrosis Factor-α-Induced Cell Death by Rottlerin through a Cytochrome-C-Independent Pathway. Experimental Cell Research, 2002, 278, 209-214.	2.6	13
46	P300 regulates the human RLIP76 promoter activity and gene expression. Biochemical Pharmacology, 2013, 85, 1203-1211.	4.4	13
47	Differential regulation of extrinsic and intrinsic cell death pathways by protein kinase C. International Journal of Molecular Medicine, 2002, 10, 541-5.	4.0	13
48	Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. International Journal of Oncology, 2008, 32, 1133-7.	3.3	13
49	Comparison of the ability of phospholipids from rat liver lysosomes to reconstitute glucocerebrosidase. Archives of Biochemistry and Biophysics, 1986, 245, 464-469.	3.0	12
50	Emerging therapeutics for targeting Akt in cancer. Frontiers in Bioscience - Landmark, 2016, 21, 757-768.	3.0	12
51	Protein kinase C-eta regulates Mcl-1 level via ERK1. Cellular Signalling, 2017, 40, 166-171.	3.6	12
52	The Enigmatic Protein Kinase C-eta. Cancers, 2019, 11, 214.	3.7	12
53	Mammalian Glucocerebrosidase: Implications for Gaucherâ \in Ms Disease. , 1989, , 3-23.		12
54	Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. International Journal of Oncology, 0, , .	3.3	10

Alakananda Basu

#	Article	IF	CITATIONS
55	Regulation of protein kinase Cδ downregulation by protein kinase Cε and mammalian target of rapamycin complex 2. Cellular Signalling, 2009, 21, 1680-1685.	3.6	10
56	PKCÎμ induces Bcl-2 by activating CREB. International Journal of Oncology, 2010, 36, 883-8.	3.3	10
57	Partial Purification and Characterization ofNaegleria fowleriβ-Glucosidase1. Journal of Protozoology, 1987, 34, 68-74.	0.8	9
58	Involvement of proteolytic activation of PKCdelta in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. International Journal of Oncology, 2005, 27, 149-54.	3.3	9
59	Sulfogalactocerebroside and bis-(monoacylglyceryl)-phosphate as activators of spleen glucocerebrosidase. Clinica Chimica Acta, 1986, 156, 179-189.	1.1	8
60	The unique protein kinase CÎ: Implications for breast cancer (Review). International Journal of Oncology, 2014, 45, 493-498.	3.3	7
61	Isolation and characterization of a fatty acyl esterase from rat lung. Archives of Biochemistry and Biophysics, 1988, 261, 384-393.	3.0	6
62	Involvement of proteolytic activation of PKCδ in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. International Journal of Oncology, 2005, 27, 149.	3.3	6
63	Article Commentary: Molecular Targets of Breast Cancer: AKTing in Concert. Breast Cancer: Basic and Clinical Research, 2008, 2, BCBCR.S787.	1.1	6
64	Differential effects of protein kinase C-eta on apoptosis versus senescence. Cellular Signalling, 2019, 55, 1-7.	3.6	6
65	Regulation of IKKÂ Expression by Akt2 Isoform. Genes and Cancer, 2011, 2, 1044-1050.	1.9	5
66	Activation of human spleen glucocerebrosidases by monoacylglycol sulfates and diacylglycerol sulfates. Archives of Biochemistry and Biophysics, 1988, 262, 345-353.	3.0	4
67	NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner. Journal of Molecular Signaling, 2010, 5, 4.	0.5	4
68	PKCε paves the way for prostate cancer. Cell Cycle, 2011, 10, 378-378.	2.6	4
69	Serum lysosomal hydrolases in cystic fibrosis. Clinica Chimica Acta, 1988, 175, 1-9.	1.1	2
70	Chapter 8 Manipulation of PKC Isozymes by RNA Interference and Inducible Expression of PKC Constructs. Methods in Enzymology, 2008, 446, 141-157.	1.0	2
71	PKC and Resistance to Chemotherapeutic Agents. , 2010, , 409-429.		2
72	Deregulation of PKB influences antiapoptotic signaling by PKC in breast cancer cells. International Journal of Oncology, 2004, 25, 671.	3.3	1

#	Article	IF	CITATIONS
73	Compartmentalized Protein Kinase C Activation in Ovarian Carcinoma Cells. , 2001, 39, 621-631.		Ο
74	Comparison of the Acidic Lipid Requirement of Control and Type 1 Gaucher's Disease Liver and Brain Glucocerebrosidases. , 1988, , 73-82.		0